Stock Analysis on Net
Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Beginner level

Historical Valuation Ratios (Summary)

Bristol-Myers Squibb Co., historical price multiples (quarterly data)

Microsoft Excel LibreOffice Calc
Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Price to earnings (P/E) 144.77 41.99 16.53 11.97 14.51 16.81 56.09 251.38 92.56 103.55 23.59 19.40 18.96 20.56
Price to operating profit (P/OP) 39.45 33.97 27.33 24.42 13.51 10.89 13.68 16.16 19.56 27.48 23.10 28.87 24.60 20.23 19.09 19.79
Price to sales (P/S) 3.28 3.16 3.66 3.97 4.45 5.52 3.87 3.11 3.21 3.67 3.64 4.38 4.04 5.02 4.85 4.40 4.59 4.72
Price to book value (P/BV) 3.73 3.55 2.87 2.82 2.77 2.80 5.30 4.63 4.91 5.89 5.89 7.67 6.65 8.88 6.75 6.05 6.36 5.66 5.56 8.36 8.38

Based on: 10-Q (filing date: 2021-04-29), 10-K (filing date: 2021-02-10), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28).

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Bristol-Myers Squibb Co.’s P/S ratio decreased from Q3 2020 to Q4 2020 but then slightly increased from Q4 2020 to Q1 2021.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Bristol-Myers Squibb Co.’s P/BV ratio increased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.

Price to Earnings (P/E)

Bristol-Myers Squibb Co., historical P/E calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 2,232,843,755 2,240,475,153 2,259,751,518 2,253,934,635 2,262,689,755 2,257,510,796 1,629,284,798 1,635,766,530 1,635,705,782 1,632,675,877 1,632,198,774 1,631,876,909 1,634,538,458 1,632,582,502 1,636,699,696 1,639,926,446 1,647,434,458 1,672,715,340 1,671,229,946 1,670,858,535 1,669,307,273
Selected Financial Data (US$)
Net earnings (loss) attributable to BMS (in millions) 2,021  (10,027) 1,872  (85) (775) (1,056) 1,353  1,432  1,710  1,160  1,901  373  1,486  (2,328) 845  916  1,574  894  1,202  1,166  1,195 
Earnings per share (EPS)2 -2.79 -4.02 -0.02 -0.25 0.42 1.52 3.47 3.79 3.14 3.01 0.88 0.23 0.56 0.62 2.58 2.80 2.94 2.66 0.00 0.00 0.00
Share price1, 3 62.89 60.00 63.75 61.33 61.04 63.97 57.37 45.40 45.64 50.65 49.21 57.92 52.04 63.87 60.95 54.24 55.67 54.78 51.96 74.66 72.26
Valuation Ratio
P/E ratio4 144.77 41.99 16.53 11.97 14.51 16.81 56.09 251.38 92.56 103.55 23.59 19.40 18.96 20.56
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 36.79 48.49 58.45 58.36 45.61 41.83 44.92 53.17 52.98 56.47 136.66 122.73 213.07 220.29 45.00 73.04 50.48 55.16
Anthem Inc. 19.99 15.87 14.35 11.97 14.80 15.96 15.55 18.14 16.19 21.45 15.64 14.84 14.70 15.44 17.72 17.04 17.09 17.48
Becton, Dickinson & Co. 49.11 86.01 95.62 75.45 90.00 65.09 83.38 66.87 72.88 408.36 105.60 206.04 49.63 59.56 30.05 28.94 36.65 32.09 43.18 41.64
Boston Scientific Corp. 304.26 13.68 13.56 11.72 11.86 51.90 42.77 28.42 33.06 73.07 89.21 363.19 354.70 44.70 46.56 83.30 96.19
CVS Health Corp. 14.44 12.88 10.69 10.20 10.94 14.15 20.65 17.46 25.50 23.08 10.05 10.69 13.42 15.08 15.71 14.91
Danaher Corp. 39.26 44.49 46.61 41.91 35.88 38.34 40.31 41.93 37.63 29.77 25.70 27.06 27.78 27.25 26.31 26.25 25.00 23.02
Edwards Lifesciences Corp. 70.70 66.48 61.28 65.79 39.74 46.05 61.52 61.07 47.99 51.14 41.12 45.24 48.67 48.16 28.95 34.05 35.04 33.48
Intuitive Surgical Inc. 89.95 87.47 82.17 70.73 44.28 48.72 49.80 51.02 53.16 53.03 73.32 73.33 69.50 70.95 45.87 42.21 38.18 37.16
Medtronic PLC 32.34 26.30 25.38 31.86 32.75 28.78 25.11 57.38 41.16 37.80 37.82 21.55 26.35 29.96 28.24 23.20 32.64 33.17
Stryker Corp. 69.46 57.72 43.23 45.35 31.33 39.24 23.72 22.60 19.64 18.96 48.55 58.86 62.59 54.36 33.60 32.52 29.96 27.92
UnitedHealth Group Inc. 23.06 20.54 17.70 16.88 19.91 20.48 17.79 17.98 17.93 21.09 21.18 20.91 20.02 20.77 23.90 23.24 22.18 21.73

Based on: 10-Q (filing date: 2021-04-29), 10-K (filing date: 2021-02-10), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28).

1 Data adjusted for splits and stock dividends.

2 Q1 2021 Calculation
EPS = (Net earnings (loss) attributable to BMSQ1 2021 + Net earnings (loss) attributable to BMSQ4 2020 + Net earnings (loss) attributable to BMSQ3 2020 + Net earnings (loss) attributable to BMSQ2 2020) ÷ No. shares of common stock outstanding
= (2,021,000,000 + -10,027,000,000 + 1,872,000,000 + -85,000,000) ÷ 2,232,843,755 = -2.79

3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Quarterly or Annual Report.

4 Q1 2021 Calculation
P/E ratio = Share price ÷ EPS
= 62.89 ÷ -2.79 =

5 Click competitor name to see calculations.


Price to Operating Profit (P/OP)

Bristol-Myers Squibb Co., historical P/OP calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 2,232,843,755 2,240,475,153 2,259,751,518 2,253,934,635 2,262,689,755 2,257,510,796 1,629,284,798 1,635,766,530 1,635,705,782 1,632,675,877 1,632,198,774 1,631,876,909 1,634,538,458 1,632,582,502 1,636,699,696 1,639,926,446 1,647,434,458 1,672,715,340 1,671,229,946 1,670,858,535 1,669,307,273
Selected Financial Data (US$)
Operating income (loss) (in millions) 1,828  (12,277) 1,342  891  859  560  1,759  1,876  1,718  1,567  1,659  513  1,379  556  992  756  1,308  999  1,335  1,161  1,135 
Operating profit per share2 -3.68 -4.10 1.62 1.81 2.23 2.62 4.25 4.17 3.34 3.13 2.52 2.11 2.25 2.21 2.48 2.68 2.92 2.77 0.00 0.00 0.00
Share price1, 3 62.89 60.00 63.75 61.33 61.04 63.97 57.37 45.40 45.64 50.65 49.21 57.92 52.04 63.87 60.95 54.24 55.67 54.78 51.96 74.66 72.26
Valuation Ratio
P/OP ratio4 39.45 33.97 27.33 24.42 13.51 10.89 13.68 16.16 19.56 27.48 23.10 28.87 24.60 20.23 19.09 19.79
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 31.39 40.69 45.82 45.19 35.87 34.03 34.32 37.50 36.74 36.64 38.12 38.00 39.99 60.88 47.72 41.32 30.85 24.25
Anthem Inc. 15.79 12.10 10.93 9.03 11.95 13.55 12.60 14.74 12.58 15.87 15.01 14.22 14.34 14.81 12.35 11.12 10.24 9.36
Becton, Dickinson & Co. 33.30 44.46 56.20 43.34 49.82 40.02 29.43 29.40 30.27 43.37 47.87 95.72 67.53 34.59 40.06 21.15 20.05 25.02 22.42 27.98 26.60
Boston Scientific Corp. 424.69 630.22 80.81 44.72 36.71 34.77 36.58 31.15 36.68 32.51 31.09 30.63 28.71 34.07 34.07 69.95 74.67
CVS Health Corp. 7.61 6.65 5.89 5.98 6.19 7.83 9.44 8.02 15.80 18.65 12.59 11.14 6.90 7.44 7.19 8.21 8.07 7.65
Danaher Corp. 32.62 36.91 46.28 43.09 35.22 34.47 29.97 30.85 26.85 23.18 20.95 21.72 22.58 22.48 22.35 21.13 20.83 21.37
Edwards Lifesciences Corp. 65.18 60.98 56.78 61.66 35.77 42.04 57.30 56.37 47.70 49.37 26.74 28.00 25.96 25.66 22.59 26.24 26.76 25.38
Intuitive Surgical Inc. 89.18 88.37 83.88 71.30 43.68 48.89 50.00 49.12 51.89 49.87 48.90 50.69 46.82 44.40 41.74 35.53 31.07 28.93
Medtronic PLC 35.86 26.29 21.01 23.52 22.21 21.26 19.74 21.13 20.04 17.64 16.73 17.82 19.53 22.64 21.53 18.18 22.35 22.18
Stryker Corp. 47.78 41.52 31.40 33.20 24.04 30.13 32.94 33.22 27.96 26.55 23.52 25.45 27.41 24.21 26.70 25.11 22.99 21.23
UnitedHealth Group Inc. 16.12 14.12 12.35 11.85 13.80 14.40 12.43 12.51 12.48 14.58 15.82 15.19 14.17 14.42 14.30 13.54 12.56 11.79

Based on: 10-Q (filing date: 2021-04-29), 10-K (filing date: 2021-02-10), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28).

1 Data adjusted for splits and stock dividends.

2 Q1 2021 Calculation
Operating profit per share = (Operating income (loss)Q1 2021 + Operating income (loss)Q4 2020 + Operating income (loss)Q3 2020 + Operating income (loss)Q2 2020) ÷ No. shares of common stock outstanding
= (1,828,000,000 + -12,277,000,000 + 1,342,000,000 + 891,000,000) ÷ 2,232,843,755 = -3.68

3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Quarterly or Annual Report.

4 Q1 2021 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 62.89 ÷ -3.68 =

5 Click competitor name to see calculations.


Price to Sales (P/S)

Bristol-Myers Squibb Co., historical P/S calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 2,232,843,755 2,240,475,153 2,259,751,518 2,253,934,635 2,262,689,755 2,257,510,796 1,629,284,798 1,635,766,530 1,635,705,782 1,632,675,877 1,632,198,774 1,631,876,909 1,634,538,458 1,632,582,502 1,636,699,696 1,639,926,446 1,647,434,458 1,672,715,340 1,671,229,946 1,670,858,535 1,669,307,273
Selected Financial Data (US$)
Revenues (in millions) 11,073  11,068  10,540  10,129  10,781  7,945  6,007  6,273  5,920  5,973  5,691  5,704  5,193  5,449  5,254  5,144  4,929  5,243  4,922  4,871  4,391 
Sales per share2 19.17 18.98 17.43 15.47 13.70 11.58 14.84 14.58 14.24 13.82 13.50 13.24 12.87 12.73 12.57 12.34 12.12 11.61 0.00 0.00 0.00
Share price1, 3 62.89 60.00 63.75 61.33 61.04 63.97 57.37 45.40 45.64 50.65 49.21 57.92 52.04 63.87 60.95 54.24 55.67 54.78 51.96 74.66 72.26
Valuation Ratio
P/S ratio4 3.28 3.16 3.66 3.97 4.45 5.52 3.87 3.11 3.21 3.67 3.64 4.38 4.04 5.02 4.85 4.40 4.59 4.72
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 5.64 6.30 6.13 5.77 5.09 4.83 4.72 4.98 4.52 4.37 3.98 3.84 3.57 3.84 3.77 3.62 3.40 3.70
Anthem Inc. 0.76 0.60 0.61 0.63 0.65 0.74 0.67 0.77 0.69 0.88 0.79 0.72 0.68 0.67 0.60 0.56 0.55 0.51
Becton, Dickinson & Co. 4.07 3.85 4.45 4.00 3.94 4.07 3.82 3.64 3.82 4.06 4.45 4.49 4.94 4.23 3.72 3.21 3.05 2.87 2.97 2.86 2.55
Boston Scientific Corp. 6.04 5.54 4.99 5.31 4.66 5.19 5.44 5.92 5.14 5.62 5.06 4.89 4.39 4.08 4.27 4.21 4.22 3.98
CVS Health Corp. 0.40 0.35 0.32 0.32 0.30 0.37 0.38 0.33 0.36 0.39 0.42 0.37 0.36 0.38 0.37 0.44 0.45 0.45
Danaher Corp. 7.27 7.01 8.15 7.48 6.34 6.29 5.32 5.43 4.67 3.97 3.62 3.74 3.77 3.70 3.52 3.32 3.35 3.48
Edwards Lifesciences Corp. 13.45 12.48 11.14 11.32 9.82 11.09 11.46 11.17 9.61 9.92 8.06 8.37 7.91 8.18 6.51 7.55 7.31 6.43
Intuitive Surgical Inc. 23.19 21.29 20.09 18.44 13.33 15.01 15.41 15.28 15.83 16.06 16.36 17.01 16.16 14.96 13.83 12.01 10.69 10.11
Medtronic PLC 5.11 4.36 4.34 4.82 4.72 4.36 4.04 4.27 4.35 3.92 3.57 3.65 3.62 4.06 3.82 3.39 4.14 4.07
Stryker Corp. 6.65 6.43 5.34 5.16 4.53 5.49 5.59 5.65 4.98 4.95 4.52 4.88 5.01 4.46 4.93 4.62 4.29 4.06
UnitedHealth Group Inc. 1.49 1.24 1.18 1.17 1.12 1.18 1.00 1.00 0.98 1.12 1.22 1.17 1.09 1.10 1.05 0.98 0.89 0.83

Based on: 10-Q (filing date: 2021-04-29), 10-K (filing date: 2021-02-10), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28).

1 Data adjusted for splits and stock dividends.

2 Q1 2021 Calculation
Sales per share = (RevenuesQ1 2021 + RevenuesQ4 2020 + RevenuesQ3 2020 + RevenuesQ2 2020) ÷ No. shares of common stock outstanding
= (11,073,000,000 + 11,068,000,000 + 10,540,000,000 + 10,129,000,000) ÷ 2,232,843,755 = 19.17

3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Quarterly or Annual Report.

4 Q1 2021 Calculation
P/S ratio = Share price ÷ Sales per share
= 62.89 ÷ 19.17 = 3.28

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Bristol-Myers Squibb Co.’s P/S ratio decreased from Q3 2020 to Q4 2020 but then slightly increased from Q4 2020 to Q1 2021.

Price to Book Value (P/BV)

Bristol-Myers Squibb Co., historical P/BV calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 2,232,843,755 2,240,475,153 2,259,751,518 2,253,934,635 2,262,689,755 2,257,510,796 1,629,284,798 1,635,766,530 1,635,705,782 1,632,675,877 1,632,198,774 1,631,876,909 1,634,538,458 1,632,582,502 1,636,699,696 1,639,926,446 1,647,434,458 1,672,715,340 1,671,229,946 1,670,858,535 1,669,307,273
Selected Financial Data (US$)
Total Bristol-Myers Squibb Company shareholders’ equity (in millions) 37,605  37,822  50,158  49,094  49,911  51,598  17,648  16,049  15,218  14,031  13,640  12,317  12,793  11,741  14,783  14,699  14,416  16,177  15,613  14,918  14,386 
Book value per share (BVPS)2 16.84 16.88 22.20 21.78 22.06 22.86 10.83 9.81 9.30 8.59 8.36 7.55 7.83 7.19 9.03 8.96 8.75 9.67 9.34 8.93 8.62
Share price1, 3 62.89 60.00 63.75 61.33 61.04 63.97 57.37 45.40 45.64 50.65 49.21 57.92 52.04 63.87 60.95 54.24 55.67 54.78 51.96 74.66 72.26
Valuation Ratio
P/BV ratio4 3.73 3.55 2.87 2.82 2.77 2.80 5.30 4.63 4.91 5.89 5.89 7.67 6.65 8.88 6.75 6.05 6.36 5.66 5.56 8.36 8.38
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 6.27 6.65 6.30 5.94 5.40 4.96 4.65 4.86 4.49 4.38 3.94 3.72 3.23 3.40 2.95 2.71 2.42 3.76 2.72 3.20 2.70
Anthem Inc. 2.78 2.19 2.10 2.06 2.23 2.42 2.13 2.40 2.15 2.82 2.45 2.24 2.26 2.24 2.04 1.84 1.82 1.72 1.31 1.45 1.62
Becton, Dickinson & Co. 3.00 2.78 3.13 3.32 3.23 3.34 3.04 2.91 3.05 3.09 3.07 2.87 2.85 3.95 3.60 4.96 4.99 4.69 4.55 4.56 3.97
Boston Scientific Corp. 3.89 3.58 3.24 3.46 3.64 4.02 5.83 6.33 5.53 6.33 5.91 6.00 5.79 5.26 4.97 5.07 5.14 4.96 4.52 5.22 4.58
CVS Health Corp. 1.51 1.33 1.24 1.24 1.21 1.47 1.47 1.23 1.25 1.29 2.17 1.95 1.73 1.88 1.94 2.34 2.38 2.15 2.18 3.01 3.10
Danaher Corp. 4.46 3.93 4.38 3.90 3.68 3.72 3.02 3.19 2.88 2.80 2.56 2.65 2.61 2.58 2.47 2.35 2.42 2.56 2.39 2.24 2.70
Edwards Lifesciences Corp. 12.91 11.97 11.56 12.74 11.29 11.62 12.48 12.65 10.65 11.76 8.72 9.39 8.40 9.51 6.82 8.30 8.39 7.28 7.64 9.86 9.78
Intuitive Surgical Inc. 10.40 9.53 9.35 9.19 7.22 8.13 8.43 8.49 8.68 8.96 9.30 10.03 9.71 9.91 8.35 7.62 7.21 4.73 4.77 5.22 5.00
Medtronic PLC 2.84 2.48 2.60 2.94 2.87 2.66 2.48 2.62 2.59 2.31 2.11 2.10 2.14 2.40 2.27 1.96 2.34 2.25 2.08 2.09 1.86
Stryker Corp. 7.24 7.05 5.85 5.69 5.17 6.38 6.60 6.72 5.92 5.74 6.09 6.72 6.92 5.56 5.73 5.51 5.21 4.82 4.59 4.81 4.65
UnitedHealth Group Inc. 5.86 4.83 4.54 4.53 4.81 4.92 4.32 4.40 4.37 4.89 5.32 5.13 4.72 4.59 4.55 4.37 4.01 3.98 3.61 3.75 3.57

Based on: 10-Q (filing date: 2021-04-29), 10-K (filing date: 2021-02-10), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28).

1 Data adjusted for splits and stock dividends.

2 Q1 2021 Calculation
BVPS = Total Bristol-Myers Squibb Company shareholders’ equity ÷ No. shares of common stock outstanding
= 37,605,000,000 ÷ 2,232,843,755 = 16.84

3 Closing price as at the filing date of Bristol-Myers Squibb Co.’s Quarterly or Annual Report.

4 Q1 2021 Calculation
P/BV ratio = Share price ÷ BVPS
= 62.89 ÷ 16.84 = 3.73

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Bristol-Myers Squibb Co.’s P/BV ratio increased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.